Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Entyvio in Newly Diagnosed Active Ulcerative Colitis
NCT03237260Phase 4Withdrawn
- Sponsor
- University of Pennsylvania
- Start
- Jul 2017
- Primary completion
- Feb 2019
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of vedolizumab in ulcerative colitis (UC), sponsored by University of Pennsylvania. Planned start Jul 2017; status: withdrawn.
02
Drugs
vedolizumab
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT03237260.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03237260.